Type 2 diabetes and cardiovascular risk: the role of GLP-1
|
|
- Douglas Miller
- 5 years ago
- Views:
Transcription
1 Type 2 diabetes and cardiovascular risk: the role of GLP-1 Dr Isidora Kitsou-Mylona, PhD Novo Nordisk Regional Medical Advisor Business Area Africa, Gulf & India
2 Disclaimer I am an employee of Novo Nordisk
3 Agenda Background on type 2 diabetes and CVD Effects of GLP-1 on CV function Effects of GLP-1 receptor agonists on CV risk factors MACE analysis for incretin therapies CV outcomes trials
4 CVD related mortality increases in patients with type 2 diabetes People with type 2 diabetes: will die 5 10 years before people without diabetes are twice as likely to have a heart attack or stroke as people who do not have diabetes are times more likely to have a lower limb amputation Other deaths CVD deaths CVD, cardiovascular disease 1 AHA in 2 Morish et al. Diabetologia 2001;44(Suppl 2):S14-S21. Lancet 1997;350(Suppl. 1):SI23 8
5 Type 2 diabetes is an independent cardiovascular risk factor Incidence of MI (%) over 7 years Without diabetes (n=1373) With diabetes (n=1059) 0 No prior MI Prior MI MI, myocardial infarction Haffner et al. N Engl J Med 1998;339:229 34
6 Diabetes and hyperglycaemia co-exist with other well-established CVD risk factors Patients with type 2 diabetes (%) Several conditions that commonly coexist with type 2 diabetes are also risk factors for micro- and macrovascular disease CVD, cardiovascular disease 1 Center for Financing, Access, and Cost Trends, AHRQ, Total Adult Population Medical Expenditure Panel Survey-Household Component, Jacobs et al. Diabetes Res Clin Pract 2005;70:263-9
7 The risk of CVD increases gradually as glucose metabolism deteriorates Rate of cardiovascular disease events (%) CVD, cardiovascular disease Khaw et al. Ann Intern Med 2004;141:413 20
8 All-cause mortality increases with increasing body mass index Yearly deaths per 1000 (95% CI) Male Female Mortality is lowest at a BMI range of kg/m 2 Each five-unit increase in BMI is associated with a 30% higher all-cause mortality Baseline BMI (kg/m 2 ) BMI, body mass index; CI, confidence interval Prospective Studies Collaboration. Lancet 2009;373:
9 Visceral adiposity is strongly associated with cardiovascular disease Frequency of cardiovascular disease (%) Male < Female < Waist circumference (cm) Waist circumference (cm) Waist circumference correlates strongly with visceral adipose tissue Balkau et al. Circulation 2007;116:
10 Effect of more vs. less intensive BPlowering regimens on CV outcomes BP (mmhg) More vs. less intensive treatment Major CV events Diabetes No diabetes Overall 6.0/ / 3.3 CV deaths Diabetes No diabetes Overall 6.0/ / 3.3 Total mortality Diabetes No diabetes Overall 6.0/ / 3.3 BP, blood pressure; CV, cardiovascular Relative risk Blood Pressure Lowering Treatment Trialists Collaboration. Arch Intern Med 2005;165:
11 Effect of more vs. less intensive BP-lowering regimens on CV outcomes BP (mmhg) More vs. less intensive treatment Stroke Diabetes No diabetes Overall 6.0/ / 3.3 CHD Diabetes No diabetes Overall 6.0/ / 3.0 Heart failure Diabetes No diabetes Overall 6.0/ / 3.3 CHD, coronary heart diseae Relative risk Blood Pressure Lowering Treatment Trialists Collaboration. Arch Intern Med 2005;165:
12 Benefit of different interventions in patients with diabetes treated for 5 years Change in CV death rate (%) CV, cardiovascular; LDL-C low-density lipoprotein-cholesterol; SBP, systolic blood pressure Ray et al. Lancet 2009;373: ; Kearney et al. Lancet 2008;371:117; Turnbull et al. Arch Intern Med 2005;165:
13 Intensive, multifactorial intervention halves the risk of macrovascular complications STENO-2 Primary composite endpoint (%) p=0.007 Conventional therapy Intensive therapy Months of follow-up Composite endpoint included cardiovascular death, myocardial infarction, revascularisation, stroke and amputation Gaede et al. N Engl J Med 2003;348:383 93
14 Agenda Background on type 2 diabetes and CVD Effects of GLP-1 on CV function Effects of GLP-1 receptor agonists on CV risk factors MACE analysis for incretin therapies CV outcomes trials
15 Physiological actions of GLP-1 relevant to cardioprotection: an overview GLP-1 receptors are expressed in the CV system, pancreas, intestines, and nervous system 1,2 GLP-1: reduces blood glucose levels 1 reduces weight 2 increases satiety 1 reduces gastric emptying 1 and calorie intake 3 reduces systolic blood pressure 1 increases diuresis 4 increases vasodilation 5 modest beneficial effects on lipids 6-9 is cardioprotective in animal models of ischaemia 10 CV, cardiovascular; GLP-1, glucagon-like peptide-1 1. Baggio and Drucker, Gastroenterology 2007;132: ; 2. Zander et al. Lancet 2002;359:824 30; 3. Verdich et al. J Clin Endocrinol Metab 2001;86:4382 9; 4. Gutzwiller et al. J Clin Endocrinol Metab 2004;89: ; 5. Basu et al. Am J Physiol Endocrinol Metab 2007;293:E ; 6. Plutzky et al. Diabetologia 2009;52(Suppl. 1):S Drucker et al. Lancet 2008;372: ; 8. Diamant et al. Lancet 2010;26;375: ; 9. Boardman et al. EASD 2011; 10. Bose et al. Diabetes 2005;54:146 51
16 Native GLP-1 has beneficial effects on endothelial function Native GLP-1: increases basal vasodilation 1 enhances acetylcholine-mediated vasodilation 1 improves endothelial function in patients with T2D and coronary artery disease 2 GLP-1, glucagon-like peptide-1; T2D, type 2 diabetes 1. Basu et al. Am J Physiol Endocrinol Metab 2007;293:E ; 2. Nyström et al. Am J Physiol Endocrinol Metab 2004;287:E
17 GLP-1 receptors on vessels and heart Cardiomyocytes Endomyocardium Vascular Endothelium GLP-1 receptors are present on vascular tissues including endothelium GLP-1, glucagon-like peptide-1 Ban et al. Circulation 2008:117;
18 Native GLP-1 improves endothelial function in patients with T2D and coronary artery disease FMD (%) change from baseline Saline p<0.05 GLP-1 FMD of the brachial artery is a measure of endothelial function FMD correlates well with endothelial dysfunction in the coronary circulation Native GLP-1 improves FMD FMD, flow-mediated dilation; GLP-1, glucagon-like peptide-1; T2D, type 2 diabetes Nyström et al. Am J Physiol Endocrinol Metab 2004;287:E
19 Native GLP-1 limits infarct size in a rat model of myocardial infarction Rat model of ischaemia Infarct size (%) * In vivo protection against MI Protection abolished by GLP-1 receptor antagonist Native GLP-1 protection mediated by the induction of multiple pro-survival kinases 0 Saline DPP-4 inhibitor Native GLP-1 + DPP-4 *p<0.001 vs. saline and DPP-4; infarction relative to the area at risk after vessel occlusion; data are mean + SE DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; MI, myocardial infarction Bose et al. Diabetes 2005;54:146 51
20 GLP-1 infusion improves left ventricular function in patients with heart failure GLP-1 + standard therapy* (n=12) Standard therapy (n=9) LVEF (%) Baseline p< weeks *Standard therapy: stable heart failure medication regimen including angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker, β-blocker, aldosterone antagonist, loop diuretic and digoxin GLP-1, glucagon-like peptide-1; LVEF, left ventricular ejection fraction Sokos et al. J Cardiac Failure 2006;12:694 99
21 Agenda Background on type 2 diabetes and CVD Effects of GLP-1 on CV function Effects of GLP-1 receptor agonists on CV risk factors MACE analysis for incretin therapies CV outcomes trials
22 In patients with type 2 diabetes, GLP-1 RAs promote weight loss Exenatide Exenatide Liraglutide Liraglutide 10 µg BID mg OW mg OD 4 7, mg OD 4 10 Change in body weight (kg) Change in waist circumference (cm) 1.6 to to to to 3.4 Not reported to to BID, twice-daily; GLP-1 RAs glucagon-like peptide-1 receptor agonists; OD, once-daily; OW, once-weekly 1. DeFronzo et al. Diabetes Care 2005;28: ; 2. Buse et al. Diabetes Care 2004;27: ; 3. Kendall et al. Diabetes Care 2005;28: ; 4. Marre et al. Diabet Med 2009;26:268 78; 5. Nauck et al. Diabetes Care 2009;32:84 90; 6. Garber et al. Lancet 2009;373:473 81; 7. Zinman et al. Diabetes Care 2009;32: ; 8. Russell-Jones et al. Diabetologia 2009;52: ; 9. Buse et al. Lancet 2009;374:39 47, 10. Pratley et al. Lancet 2010;375: ; 11. Data on file, Novo Nordisk; 12. Drucker et al. Lancet 2008;372: ; 13. Bergenstal et al. Lancet 2010;376:431 9; 14. Diamant et al. Lancet 2010;26;375: ; 15. Boardman et al. EASD 2011; 16. Blevins et al. J Clin Endocrinol Metab 2011;96: ; 17. Buse et al. EASD 2011
23 Weight change across the LEAD programme LEAD-3 Monotherapy LEAD-2 MET combination LEAD-1 SU combination LEAD-4 MET + TZD combination LEAD-5 MET + SU combination LEAD-6 MET ± SU combination Lira vs. Sita MET combination Baseline (kg) Change in body weight (kg) *** *** NR NR NR NR NR NR NR *** *** *** *** *** *** *** *** *** Liraglutide 1.2 mg Liraglutide 1.8 mg Glimepiride Rosiglitazone Glargine Placebo Exenatide Sitagliptin *p<0.01, ***p vs. active comparator; p 0.01, p vs. placebo. [Active comparators vs. placebo not shown]. Data from core trials LEAD: Liraglutide Effect and Action in Diabetes. Marre et al. Diabet Med 2009;26; (LEAD-1); Nauck et al. Diabetes Care 2009;32;84 90 (LEAD-2); Garber et al. Lancet 2009;373: (LEAD-3); Zinman et al. Diabetes Care 2009;32: (LEAD-4); Russell-Jones et al. Diabetologia 2009;52: (LEAD-5); Buse et al. Lancet 2009;374:39 47 (LEAD-6); Pratley et al. Lancet 2010;375: (lira vs. sita)
24 Liraglutide consistently reduces SBP All subjects. ***p , **p<0.001, *p<0.05 vs. comparator Marre et al. Diabetic Med 2009;26; (LEAD-1); Nauck et al. Diabetes Care 2009;32;84 90 (LEAD-2); Garber et al. Lancet 2009;373: (LEAD-3); Zinman et al. Diabetes Care 2009;32: (LEAD-4); Russell-Jones et al. Diabetologia 2009;52: (LEAD-5); Buse et al. Lancet 2009; 374:39 47 (LEAD-6); Pratley et al. Lancet 2010:375; (lira DPP-4i)
25 Liraglutide improves SBP further in type 2 patients with higher SBP at baseline Fonseca et al. Diabetes 2009;58(Suppl. 1):A146.
26 SBP reduction with liraglutide independent of concomitant antihypertensives Reductions with liraglutide were seen in overall patient group ( 2.55 mmhg; p<0.01 vs. baseline) and in those not taking or taking antihypertensive (AH) medication Additional SBP reductions with liraglutide can be achieved on top of reductions from concomitant AH medications *p<0.05; **p<0.001 vs. baseline Fonseca et al. Diabetes 2010;59(Suppl. 1):A79 (296-OR)
27 Proposed Mechanisms for a Beneficial Impact of GLP-1 and GLP-1RAs on Blood Pressure Increased urine volume and sodium excretion 1 3 Increased baseline and ACh-induced vasodilation independent of alterations in glucose or insulin concentrations 1,3 ACh, acetylcholine; CV, cardiovascular; GLP-1, glucagon-like peptide Baggio & Drucker. Gastroenterology. 2007;132: ; 2. Gutzwiller et al. J Clin Endocrinol Metab. 2004;89: ; 3. Basu et al. Am J Physiol Endocrinol Metab. 2007;293:E1289-E1295.
28 Liraglutide Improves Mean Post-prandial Triglyceride Profiles in Subjects With T2D 4.0 Liraglutide 1.8 mg Placebo Triglycerides (mmol/l) Time after meal (h) Data are mean±se. SE, standard error; T2D, type 2 diabetes. Hermansen et al. Diabetes. 2012;61(suppl 1):A272 (1058-P).
29 Liraglutide Reduces Fasting Lipid Levels in Patients With T2D LEAD 1-6: meta-analysis Total cholesterol LDL-C Triglyceride *** *** ** *** ** LDL-C, low-density lipoprotein cholesterol; T2D, type 2 diabetes. *p<0.05; **p<0.01; ***p< all vs. baseline; is used instead of * to indicate a significant increase from baseline. Fonseca et al. International Diabetes Federation 21st World Diabetes Congress, 4-8 December 2011, Dubai, UAE.
30 Proposed Mechanisms for a Beneficial Impact of GLP- 1 and GLP-1RAs on Post-prandial Lipid Profiles Ileal brake effects on nutrient absorption and lymph flow 1 Inhibition of hepatic VLDL-TG production (does not change the VLDL composition) 2 Altered hepatic expression of genes involved in VLDL production, lipogenesis, and lipid homeostasis 2 GLP-1, glucagon-like peptide-1; GLP-1RAs, glucagon-like peptide-1 receptor agonists; TG, triglycerides; VLDL, very-low-density lipoprotein. 1. Qin et al. Am J Physiol Gastrointest Liver Physiol. 2005;288:G943-G949; 2. Parlevliet et al. PLOS One. 2012;7:e49-e52.
31 Agenda Background on type 2 diabetes and CVD Effects of GLP-1 on CV function Effects of GLP-1 receptor agonists on CV risk factors MACE analysis for incretin therapies CV outcomes trials
32 FDA guidance for industry In December 2008, the US FDA issued guidance to industry for evaluating CV safety in diabetes drugs Industry should demonstrate new therapy will not result in an unacceptable increase in CV risk The upper bound of the two-sided 95% CI of the risk ratio should be <1.8 CI, confidence interval; CV, cardiovascular; FDA, Food and Drug Administration FDA. Guidance for Industry: Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
33 FDA guidance for CV safety studies For new studies in the planning stage: CV events in all phase 2 and 3 trials should be prospectively adjudicated by an independent committee A meta-analysis should be performed on completion To obtain sufficient endpoints, patients at high risk of CV events should be included A protocol describing the statistical methods for the meta-analysis should be provided Similarities and/or differences between subgroups (e.g. age, sex, race, etc.) should be explored if possible CV, cardiovascular; FDA, Food and Drug Administration FDA. Guidance for Industry: Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
34 FDA guidance for CV safety studies For completed studies prior to new drug application: Perform an integrated meta-analysis of phase 2/3 trials to compare CV events in patients randomised to the investigational drug vs. control Demonstrate that the new therapy will not result in an unacceptable CV risk Estimated risk ratio for the upper bound of the two-sided CI for the investigational drug should be <1.8 If upper CI= , a postmarketing CV surveillance trial may be required to demonstrate safety CI, confidence interval; CV, cardiovascular; FDA, Food and Drug Administration FDA. Guidance for Industry: Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
35 Exenatide is not associated with an increased CV risk FDA upper bound 95% criterion for approvability Primary MACE 0.70 Secondary MACE Risk ratio Exenatide better Control better CV, cardiovascular; FDA, food and drugs administration; MACE, major adverse cardiovascular event(s) Ratner et al. BMC Cardiovascular Diabetology 2011;10:22
36 Summary of exenatide MACE analysis The hazard ratio point estimates were <1 for the primary and secondary MACE analyses with the upper 95% confidence limits <1.8 Exenatide does not appear to increase the risk of cardiovascular risk in T2D patients MACE, major adverse cardiovascular event(s); T2D, type 2 diabetes
37 MACE analysis of sitagliptin Pooled analysis of 19 double-blind randomised studies in T2D MACE incidence rate/100 patient-years (64 total events) Sitagliptinexposed (100 mg OD) (n=5429) Non-exposed (placebo or active comparator) (n=4817) Betweengroup difference [95% CI] [ 0.7 to 0.1] Risk ratio [95% CI] 0.68 [0.41 to 1.12] CI, confidence interval; MACE, major adverse cardiovascular event(s); T2D, type 2 diabetes Williams-Herman et al. BMC Endocrine Disorders 2010;10:7
38 Summary of sitagliptin MACE analysis The MACE analysis revealed 0.6 events per 100 patient-years for sitagliptin-treated patients compared with 0.9 events per 100 patient-years for non-exposed patients Sitagliptin does not appear to increase the risk of cardiovascular events in T2D patients The impact of sitagliptin on CV outcomes will be investigated in the TECOS trial CV, cardiovascular; MACE, major adverse cardiovascular event(s); T2D, type 2 diabetes; TECOS, Sitagliptin Cardiovascular Outcome Study
39 Saxagliptin is not associated with an increased CV risk Primary MACE Cox hazard ratio Incidence rate ratio Incidence ratio Secondary MACE Cox hazard ratio Incidence rate ratio Incidence ratio Acute CV events Cox hazard ratio Incidence rate ratio Incidence ratio FDA upper bound 95% criterion for approvability Ratio of saxagliptin to control Saxagliptin better Control better CV, cardiovascular; FDA, Food and Drug Administration; MACE, major adverse cardiovascular event(s) FDA. Briefing document Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM pdf; Frederich et al. Postgrad Med 2010;122:16 27
40 Summary of saxagliptin MACE analysis Overall, the saxagliptin MACE analysis demonstrated consistent results No evidence for increased CV risk with saxagliptin use In each pooled assessment, the point estimate of the relative risk was always <1, with the upper 95% confidence limit <1.4 CV, cardiovascular; MACE, major adverse cardiovascular event(s)
41 MACE analysis for linagliptin Primary CV endpoint, incidence rate/1000 PY Secondary CV endpoints, incidence rate/1000 PY CV death, stroke or MI All adjudicated CV events FDA-custom MACE Tertiary CV endpoints, incidence rate/1000 PY CV death Nonfatal MI Nonfatal stroke TIA Hospitalisation for unstable angina pectoris Linagliptin (n=3319) Comparator (n=1920) Hazard ratio (95% CI) (0.16,0.70) * (0.17,0.78) * 0.55 (0.33,0.94) * 0.34 (0.15,0.75) * 0.74 (0.10,5.33) 0.52 (0.17,1.54) 0.11 (0.02,0.51) * 0.17 (0.02,1.53) 0.24 (0.02,2.34) *Significantly lower hazard ratio (upper 95% CI <0.01; p<0.05) CV, cardiovascular; FDA, Food and Drug Administration; MACE, major adverse cardiovascular event(s); MI, myocardial infarction; PY, patient-year; TIA, transient ischaemic attack Johansen et al. Diabetes 2011;60(Suppl. 1A):LB9
42 MACE analysis for linagliptin conclusions A greater than 30% excess risk of CV events with linagliptin vs. comparators was ruled out by linagliptin s MACE meta-analysis However, the FDA did not considered this result robust because: The trials were not prospectively designed to evaluate CV safety The population included was at low risk for CV events There were inconsistent findings in sensitivity analyses Thus, the FDA requested the conduct of a post-approval CV outcomes trial CV, cardiovascular; FDA, Food and Drug Administration; MACE, major adverse cardiovascular event(s) Johansen et al. Diabetes 2011;60(Suppl. 1A):LB9
43 MedDRA definitions of cardiovascular events used in MACE analysis of liraglutide CV death FDA list of adverse events Custom MACE MI: 6 terms Stroke: 30 terms MedDRA-defined list (narrow) MI: 10 terms Stroke: 95 terms SMQ Narrow MedDRA-defined list (broad) MI: 28 terms Stroke: 125 terms SMQ Broad CV, cardiovascular; FDA, US Food and Drug Administration; MACE, major adverse cardiovascular event(s) MedDRA, Medical Dictionary for Regulatory Activities; MI, myocardial infarction; SMQ, standard MedDRA query defined list of adverse events belonging to the same category Marso et al. Diab Vasc Dis Res 2011;8:237 40
44 Liraglutide is not associated with an increased CV risk IR 95% CI Number of events SMQ, broad 0.73 (0.38;1.41) 39 SMQ, narrow 0.73 (0.38;1.41) 39 Custom 0.72 (0.35;1.50) Incidence ratio CI, confidence interval; CV, cardiovascular; IR, incidence ratio; SMQ, standard Medical Dictionary for Regulatory Activities query Marso et al. Diab Vasc Dis Res 2011;8:237 40
45 Agenda Background on type 2 diabetes and CVD Effects of GLP-1 on CV function Effects of GLP-1 receptor agonists on CV risk factors MACE analysis for incretin therapies CV outcomes trials
46 LEADER : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
47 LEADER trial design Inclusion criteria T2D patients: HbA 1c 7.0% Antidiabetic drug naïve or treated with one or more OADs or treated with basal or premix insulin (alone or in combination with OADs) Run-in 2 weeks R A N D O M I S A T I O N Standard of care + liraglutide Double-blinded treatment months Standard of care + placebo High-risk CV profile Clinicaltrials.gov identifier: NCT First patient first visit: 1 September 2010 Last patient last visit: January 2016 (estimated) Approximately 9000 patients enrolled in more than 30 countries Several visits during first 6 months, then one visit every 6 months for up to 4.5 years CV, cardiovascular; OADs, oral antidiabetic drugs; T2D, type 2 diabetes
48 LEADER trial objective and primary endpoint Trial objective To determine the long-term effect of liraglutide on CV outcomes and other clinically important events in high CVD risk adults with T2D Primary endpoint First occurrence of either CV death, nonfatal MI or non-fatal stroke CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction; T2D, type 2 diabetes
49 CV outcome trials overview Trial Company Drug Timing of initiation LEADER Liraglutide Post-approval EXSCEL Exenatide QW Post-approval ELIXA Lixisenatide Pre-approval REWIND Dulaglutide Pre-approval SAVOR-TIMI 53 Saxagliptin Post-approval EXAMINE Alogliptin Pre-approval CAROLINA Linagliptin Pre-approval TECOS Sitagliptin Post-approval Duration Start end 5 years Sep years June years June years July years May Up to 4.75 years Sep years Oct Up to 5 years Dec QW, once weekly
50 Thank you
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationCardiovascular Safety of Incretin Based Therapy
Cardiovascular Safety of Incretin Based Therapy John B. Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Executive Associate Dean, Clinical Research University of
More informationCONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE. AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY. sul Paziente ad alto rischio CV*
CONTROLLO GLICEMICO E RISCHIO CARDIOVASCOLARE AGOSTINO CONSOLI DMSI - Università d Annunzio CHIETI ITALY sul Paziente ad alto rischio CV* Does reducing hyperglycemia protect against cardiovascular risk?
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More information10/27/2011. Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials. Disclaimer
Challenges in Anti-diabetic Global Drug Development A Shift from Surrogate to Outcome Trials Eckhard Leifke, MD PhD Senior Medical Director Takeda Global Research Development Center, Inc. Presentation
More informationRegulatory Experience in Reviewing CV Safety for Diabetes
Regulatory Experience in Reviewing CV Safety for Diabetes Drugs Kristina Dunder MD, PhD, Alternate CHMP member MPA, Sweden Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationIncretin-Based therapy for type 2 diabetes: overcoming unmet needs
2 : 15 Incretin-Based therapy for type 2 diabetes: overcoming unmet needs Diabetes is a progressive disease characterised by impaired betacell function, and reduced insulin sensitivity and secretion. Over
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationFaculty. Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY
Faculty Robert S. Busch, MD, FACE Director of Clinical Research Albany Medical Faculty: Community Endocrine Group Albany, NY 2 Disclosures Robert S. Busch, MD, FACE serves as a speaker for Astra Zeneca,
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationGlucagon-like peptide-1 (GLP-1) is an
THE NEW SCIENCE OF GLP-1: EFFECTS BEYOND GLUCOSE CONTROL Richard E. Pratley, MD ABSTRACT The incretin hormone, glucagon-like peptide- 1 (GLP-1) has well-characterized effects on glucose homeostasis that
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationCARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE
CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence
More informationParenteral Agents in Type 2 DM
Parenteral Agents in Type 2 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationCardiovascular risk in diabetes: What the Cardiologist Needs to Know. Hani Sabbour MD FACC FHRS
Cardiovascular risk in diabetes: What the Cardiologist Needs to Know Hani Sabbour MD FACC FHRS Years of life lost Hazard ratio (95% CI) (diabetes vs. no diabetes) CVD is the leading cause of death among
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationLe incretine: un passo avanti. Francesco Dotta
Le incretine: un passo avanti Francesco Dotta U.O.C. Diabetologia, Policlinico Le Scotte Università di Siena Fondazione Umberto Di Mario ONLUS Toscana Life Science Park Incretins: multiple targets multiple
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGlycemic control what can be achieved with life-style and when and how to use pharmacological agents?
Glycemic control what can be achieved with life-style and when and how to use pharmacological agents? Eberhard Standl Munich Diabetes Research Institute At the Munich Helmholtz Center Pathogenetic key
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More information